Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. [Phase 1]

View source ↗

Summary

Forte Biosciences is running a Phase 1 study to evaluate the safety and efficacy of FB102 in patients with severe to very severe alopecia areata; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• FB102

Snippet

Sponsor: Forte Biosciences, Inc. | Conditions: Alopecia Areata | Phase 1 | Status: RECRUITING